ALLO-647 + Fludarabine + Cyclophosphamide
Phase 2Terminated 2 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Large B Cell Lymphoma
Conditions
Relapsed/Refractory Large B Cell Lymphoma
Trial Timeline
Nov 1, 2023 → Oct 28, 2024
NCT ID
NCT05714345About ALLO-647 + Fludarabine + Cyclophosphamide
ALLO-647 + Fludarabine + Cyclophosphamide is a phase 2 stage product being developed by Allogene Therapeutics for Relapsed/Refractory Large B Cell Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05714345. Target conditions include Relapsed/Refractory Large B Cell Lymphoma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Large B Cell Lymphoma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05714345 | Phase 2 | Terminated |
| NCT05000450 | Phase 1/2 | Terminated |
| NCT04696731 | Phase 1 | Active |
| NCT04416984 | Phase 1/2 | Active |
| NCT03939026 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Large B Cell Lymphoma